Compare ADMA Biologics Inc (ADMA) vs Angi Inc (ANGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Angi Inc — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Angi Inc trades at $6.14 (market cap $260.08M). The key difference: ADMA Biologics Inc is far larger — about 8.2× Angi Inc's market cap. Which is the better fit depends on your goals.
| ADMA | ANGI | |
|---|---|---|
Market Cap | $2.13B | $260.08M |
Sector | Health | Media |
52-Week High | $20.38 | $18.90 |
52-Week Low | $7.60 | $4.78 |
Enterprise Value | $2.20B | $486.89M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ANGI trades at $6.44, up 6.27% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue declined to $1.03B in 2025, though net income improved to $43.83M. Valuation ratios appear low with P/E of 14.86 and P/S of 0.27. Recent news highlights an AI strategy pivot and multiple law firm fraud investigations, creating uncertainty.
The stock offers potential upside to the $9.20 consensus price target, but risks include declining revenue, negative cash flows, and legal scrutiny. Analyst sentiment is cautious with 62.97% hold ratings. Execution of the AI transition and resolution of legal issues are critical for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →
